Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Krebs Biochemicals & Industries's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krebs Biochemicals & Industries OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krebs Biochemicals & Industries's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Krebs Biochemicals & Industries's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krebs Biochemicals & Industries (BOM:524518) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Krebs Biochemicals & Industries and its competitors. According to the industry distribution chart, Krebs Biochemicals & Industries ranks #776 out of 961 companies in the Drug Manufacturers industry, placing it in the top 80.7%.
Is Krebs Biochemicals & Industries' OCF Margin % too high?
Krebs Biochemicals & Industries' current OCF Margin % is 0.00%. Based on the distribution chart, Krebs Biochemicals & Industries ranks #776 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Krebs Biochemicals & Industries has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krebs Biochemicals & Industries' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Krebs Biochemicals & Industries ranks #776 out of 961 companies for OCF Margin %. This places Krebs Biochemicals & Industries in the lower half of its industry. The industry median OCF Margin % is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.80, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Krebs Biochemicals & Industries and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krebs Biochemicals & Industries's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krebs Biochemicals & Industries stock overvalued right now?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries (BOM:524518) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹37.88, compared to a current price of ₹57.25 — trading 51.1% above its estimated fair value. The current OCF Margin % is 0.00%. Krebs Biochemicals & Industries' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Krebs Biochemicals & Industries (BOM:524518), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krebs Biochemicals & Industries (BOM:524518) Overvalued in 2026?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries stock appears to be overvalued.
The current stock price of ₹57.25 is trading 51.1% above its estimated GF Value™ of ₹37.88.
GuruFocus considers Krebs Biochemicals & Industries to be Significantly Overvalued.
Key valuation signals for BOM:524518:
OCF Margin %: 0.00%
GF Value™: ₹37.88 vs. price of ₹57.25 (51.1% above fair value)
No single metric tells the full story. See the BOM:524518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.
40GF Score
Get the complete analysis for BOM:524518
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524518 has been successfully added to your 
